Pub Date : 2025-12-09DOI: 10.1186/s40360-025-01039-2
Hisham A Nematalla, Mona Elharoun, Mohammad M Abd-Alhaseeb, Hend A Sharafeldin, Manal A Elsheikh, Haidy Abbas, Amr Elkelish, Komla Mawunyo Dossouvi, Amir E Mehana, Fathy Elsayed Abdelgawad, Mariam Zewail
Background: Tremors and rigid muscles are symptoms of Parkinson's disease (PD), which affects about 1% of the global population.
Purpose: To investigate the integrated therapeutic benefits of the phytopharmaceutical berberine and mucoadhesive nanoliposomes, administered via the nose-to-brain route, to enhance bioavailability, facilitate blood-brain barrier penetration, and augment efficacy against neurodegenerative progression in Parkinson's disease (PD).
Study design: This study aimed to develop and characterize chitosan-decorated liposomes (chitosomes) loaded with berberine (BER) for targeted brain delivery via the intranasal route.
Methods: In vitro characterization of BER loaded chitosomes was conducted including measurement of particle size, zeta potential, EE % and in vitro drug release. The optimized formulation was intranasally administered in rats with rotenone-induced PD animal model, motor function and coordination were investigated besides testing the levels of different biomarkers and histopathological examination.
Results: The prepared chitosomes had a particle size of 312 nm, zeta potential of 34 mV, and high encapsulation efficiency (89.3%) and sustained drug release. In vivo assessments conducted in a rotenone-induced PD animal model revealed notable improvements in motor function and coordination. Biochemical evaluations showed that BER chitosomes reduced α-synuclein by 49% and raised dopamine levels by 55% as compared to the model group. Additionally, BER chitosomes significantly decreased oxidative stress markers by a 67% decrease in NF-κB levels and a one-fold increase in Nrf2. Histological examination showed a noticeable reduction in neuronal degeneration and Lewy body formation.
Conclusion: Our findings imply that BER chitosomes are a viable intranasal delivery tool for the efficient treatment of PD due to their enhanced bioavailability. and greater nasal mucosa penetration.
{"title":"Innovative approach in Parkinson's targeting via berberine-loaded mucoadhesive surface-modified liposomes: a multi-faceted study.","authors":"Hisham A Nematalla, Mona Elharoun, Mohammad M Abd-Alhaseeb, Hend A Sharafeldin, Manal A Elsheikh, Haidy Abbas, Amr Elkelish, Komla Mawunyo Dossouvi, Amir E Mehana, Fathy Elsayed Abdelgawad, Mariam Zewail","doi":"10.1186/s40360-025-01039-2","DOIUrl":"10.1186/s40360-025-01039-2","url":null,"abstract":"<p><strong>Background: </strong>Tremors and rigid muscles are symptoms of Parkinson's disease (PD), which affects about 1% of the global population.</p><p><strong>Purpose: </strong>To investigate the integrated therapeutic benefits of the phytopharmaceutical berberine and mucoadhesive nanoliposomes, administered via the nose-to-brain route, to enhance bioavailability, facilitate blood-brain barrier penetration, and augment efficacy against neurodegenerative progression in Parkinson's disease (PD).</p><p><strong>Study design: </strong>This study aimed to develop and characterize chitosan-decorated liposomes (chitosomes) loaded with berberine (BER) for targeted brain delivery via the intranasal route.</p><p><strong>Methods: </strong>In vitro characterization of BER loaded chitosomes was conducted including measurement of particle size, zeta potential, EE % and in vitro drug release. The optimized formulation was intranasally administered in rats with rotenone-induced PD animal model, motor function and coordination were investigated besides testing the levels of different biomarkers and histopathological examination.</p><p><strong>Results: </strong>The prepared chitosomes had a particle size of 312 nm, zeta potential of 34 mV, and high encapsulation efficiency (89.3%) and sustained drug release. In vivo assessments conducted in a rotenone-induced PD animal model revealed notable improvements in motor function and coordination. Biochemical evaluations showed that BER chitosomes reduced α-synuclein by 49% and raised dopamine levels by 55% as compared to the model group. Additionally, BER chitosomes significantly decreased oxidative stress markers by a 67% decrease in NF-κB levels and a one-fold increase in Nrf2. Histological examination showed a noticeable reduction in neuronal degeneration and Lewy body formation.</p><p><strong>Conclusion: </strong>Our findings imply that BER chitosomes are a viable intranasal delivery tool for the efficient treatment of PD due to their enhanced bioavailability. and greater nasal mucosa penetration.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"209"},"PeriodicalIF":2.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12690832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Cancer has become a global health threat with increasing incidence & mortality rates, and despite significant advancements in diagnostics and therapeutics, they limited for aggressive cancers like pancreatic ductal adenocarcinoma (PDAC). To note, KRAS-mutated PDAC is very frequent and limited by potent therapeutics due to their aggressiveness. Drug repurposing has become a potent strategy due to cost-effective, established safety & toxicity profiles. Sitagliptin and Linagliptin are Dipeptidyl Peptidase-4 (DPP-4) inhibitors, which are being used to manage Type 2 Diabetes Mellitus (T2DM). Recent studies have indicated that they have the potential to induce apoptotic-mediated cell death in cancer.
Methods: In the current study, we examined the therapeutic potential of these DPP-4 inhibitors in proliferation, wound healing, and colony formation, ROS induction, DNA fragmentation, apoptosis induction, and regulation of gene expression in KRAS G12C-mutated MIA PaCa-2 & KRAS G12D-mutated PANC-1 PDAC cells. Additionally, the network pharmacology, Gene Ontology (GO) & KEGG pathways enrichment were also studied for DPP-4 inhibitors in PDAC.
Results: The results indicated that both drugs inhibited the proliferation, migration, & colony formation; elevated intracellular ROS levels; induced DNA fragmentation, regulated MAPK & apoptosis-related gene expression, and induced apoptosis confirmed by flow cytometry. In addition, the network pharmacology analysis supported that the identified hub genes plays a role in apoptosis.
Conclusions: Overall, we report that Sitagliptin and Linagliptin have significant anticancer potential towards KRAS-mutated PDAC. Furthermore, we recommend repurposing of more drugs to examine their anti-cancer potential towards these aggressive cancers and to overcome clinical resistance in the near future.
{"title":"Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma.","authors":"Prasanna Srinivasan Ramalingam, Md Sadique Hussain, Gayathri Chellasamy, Sujatha Elangovan, Divya Sharma, Premkumar T, Rudra Awdhesh Kumar Mishra, Gothandam Kodiveri Muthukaliannan, Tajamul Hussain, Salman Alrokayan, Purushothaman Balakrishnan, Janaki Ramaiah Mekala, Sivakumar Arumugam","doi":"10.1186/s40360-025-01020-z","DOIUrl":"10.1186/s40360-025-01020-z","url":null,"abstract":"<p><strong>Background: </strong>Cancer has become a global health threat with increasing incidence & mortality rates, and despite significant advancements in diagnostics and therapeutics, they limited for aggressive cancers like pancreatic ductal adenocarcinoma (PDAC). To note, KRAS-mutated PDAC is very frequent and limited by potent therapeutics due to their aggressiveness. Drug repurposing has become a potent strategy due to cost-effective, established safety & toxicity profiles. Sitagliptin and Linagliptin are Dipeptidyl Peptidase-4 (DPP-4) inhibitors, which are being used to manage Type 2 Diabetes Mellitus (T2DM). Recent studies have indicated that they have the potential to induce apoptotic-mediated cell death in cancer.</p><p><strong>Methods: </strong>In the current study, we examined the therapeutic potential of these DPP-4 inhibitors in proliferation, wound healing, and colony formation, ROS induction, DNA fragmentation, apoptosis induction, and regulation of gene expression in KRAS G12C-mutated MIA PaCa-2 & KRAS G12D-mutated PANC-1 PDAC cells. Additionally, the network pharmacology, Gene Ontology (GO) & KEGG pathways enrichment were also studied for DPP-4 inhibitors in PDAC.</p><p><strong>Results: </strong>The results indicated that both drugs inhibited the proliferation, migration, & colony formation; elevated intracellular ROS levels; induced DNA fragmentation, regulated MAPK & apoptosis-related gene expression, and induced apoptosis confirmed by flow cytometry. In addition, the network pharmacology analysis supported that the identified hub genes plays a role in apoptosis.</p><p><strong>Conclusions: </strong>Overall, we report that Sitagliptin and Linagliptin have significant anticancer potential towards KRAS-mutated PDAC. Furthermore, we recommend repurposing of more drugs to examine their anti-cancer potential towards these aggressive cancers and to overcome clinical resistance in the near future.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"208"},"PeriodicalIF":2.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-03DOI: 10.1186/s40360-025-01048-1
Namık Bilici, Ferhat Bozduman
Background: Fluconazole (FCZ), a triazole antifungal agent, is routinely used in the treatment of various Candida infections, including oropharyngeal, esophageal, vulvovaginal candidiasis, candidemia, and disseminated candidiasis. Despite its broad safety profile, superior efficacy, and favorable pharmacokinetics, resistance to FCZ is an increasing clinical challenge. Zinc undecylenate (ZU), derived from castor oil, is an established topical antifungal agent with additional dermatological protective and immunoendocrinological properties. Combining these two pharmacotherapeutic agents presents a promising approach to overcoming fungal resistance, preventing biofilm formation, and reducing recurrence rates.
Methods: In this study, powdered ZU was condensed with powdered FCZ using low-pressure radiofrequency plasma (LPRFP). This plasma-assisted approach enabled the creation of a compound with sequential antifungal mechanisms. The condensed FCZ-ZU product was characterized and validated using nuclear magnetic resonance (NMR), optical emission spectrometry (OES), scanning electron microscopy (SEM), zeta potential, and particle size analyses. Statistical significance was determined using zeta potential and particle size data, with results evaluated at a threshold of p < 0.0001.
Results: The plasma-condensed FCZ-ZU compound demonstrated distinct physicochemical properties compared to the parent FCZ and ZU powders. Characterization confirmed the structural modification and condensation process, while particle size and zeta potential analyses indicated significant differences, supporting the creation of a novel compound (p < 0.0001). The sequential mechanism of action between FCZ and ZU suggested enhanced antifungal efficacy, reduced likelihood of resistance development, and inhibition of biofilm formation.
Conclusions: This study successfully demonstrated, for the first time, the plasma-assisted condensation of FCZ with ZU into a single antifungal preparation. The novel compound has the potential to shorten treatment duration, prevent relapse, and overcome resistance in persistent and recurrent mycosis infections. The findings highlight LPRFP as a promising method for combining multiple pharmacotherapeutic agents into innovative formulations with enhanced clinical potential.
{"title":"Condensation of fluconazole and zinc undecylanate particles using low-pressure RF plasma: a novel drug combination approach.","authors":"Namık Bilici, Ferhat Bozduman","doi":"10.1186/s40360-025-01048-1","DOIUrl":"https://doi.org/10.1186/s40360-025-01048-1","url":null,"abstract":"<p><strong>Background: </strong>Fluconazole (FCZ), a triazole antifungal agent, is routinely used in the treatment of various Candida infections, including oropharyngeal, esophageal, vulvovaginal candidiasis, candidemia, and disseminated candidiasis. Despite its broad safety profile, superior efficacy, and favorable pharmacokinetics, resistance to FCZ is an increasing clinical challenge. Zinc undecylenate (ZU), derived from castor oil, is an established topical antifungal agent with additional dermatological protective and immunoendocrinological properties. Combining these two pharmacotherapeutic agents presents a promising approach to overcoming fungal resistance, preventing biofilm formation, and reducing recurrence rates.</p><p><strong>Methods: </strong>In this study, powdered ZU was condensed with powdered FCZ using low-pressure radiofrequency plasma (LPRFP). This plasma-assisted approach enabled the creation of a compound with sequential antifungal mechanisms. The condensed FCZ-ZU product was characterized and validated using nuclear magnetic resonance (NMR), optical emission spectrometry (OES), scanning electron microscopy (SEM), zeta potential, and particle size analyses. Statistical significance was determined using zeta potential and particle size data, with results evaluated at a threshold of p < 0.0001.</p><p><strong>Results: </strong>The plasma-condensed FCZ-ZU compound demonstrated distinct physicochemical properties compared to the parent FCZ and ZU powders. Characterization confirmed the structural modification and condensation process, while particle size and zeta potential analyses indicated significant differences, supporting the creation of a novel compound (p < 0.0001). The sequential mechanism of action between FCZ and ZU suggested enhanced antifungal efficacy, reduced likelihood of resistance development, and inhibition of biofilm formation.</p><p><strong>Conclusions: </strong>This study successfully demonstrated, for the first time, the plasma-assisted condensation of FCZ with ZU into a single antifungal preparation. The novel compound has the potential to shorten treatment duration, prevent relapse, and overcome resistance in persistent and recurrent mycosis infections. The findings highlight LPRFP as a promising method for combining multiple pharmacotherapeutic agents into innovative formulations with enhanced clinical potential.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145666990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1186/s40360-025-01036-5
Maysara S El-Salakawy, Alshimaa A Abd-Elmoneam, Mohammed S Nofal, Nourhan M Kolaib, Amany A Elkashef, Ahmed Z Ghareeb, Doaa A Ghareeb
Background: Inflammation and oxidative stress strongly contribute to the pathophysiology of acute respiratory distress syndrome (ARDS), which is a life-threatening pulmonary disease. Zinc oxide/berberine nanoparticles (ZnO/Ber-NPs) have been shown to have a protective effect against COVID-19 because of their antioxidant, anti-inflammatory, and antiviral properties. Hence, this study aimed to investigate the therapeutic action of ZnO/Ber NPs against ARDS. ARDS was induced by a combination of lipopolysaccharides and nicotine (LPS + Nt).
Methods: Male mice were induced with LPS + Nt alternately for 14 days and then orally administered berberine (Ber) (1.24 mg/kg), ZnO NPs (2.06 mg/kg), a ZnO NP + Ber mixture (3.3 mg/kg), or ZnO/Ber NPs (3.3 mg/kg). Assessment of (1) prooxidant and antioxidant (enzymatic and nonenzymatic) parameters, (2) inflammatory and anti-inflammatory markers (TNF-α, IL-1β, IFN-ɣ, NF-kB and IL-10), (3) lung lesion parameters, triggering receptor expressed on myeloid cells-1 (TREM-1), myeloperoxidase enzyme (MPO) and angiotensin-converting enzyme-2 (ACE II), (4) and apoptotic markers (Bax and p53) were performed via standardized methods. In addition, ZnO, Ber, and ZnO/Ber NPs were examined for their bioactivities against the following proteins GPx, code: 2R37, SOD protein, code: 1PL4, ACE2 protein, code: 6M1D, TREM1 protein, code: 1Q8M and MPO protein, code: 6WYZ.
Results: The results demonstrated that LPS + Nt administration significantly elevated oxidative stress, proinflammatory, lung lesion, and proapoptotic parameters while reducing antioxidant and ACE II levels in the lung. Treatments, especially ZnO/Ber NPs, significantly attenuated the oxidative stress and inflammation associated with ARDS, as indicated by the restoration of antioxidant enzyme activities, decreased lipid peroxidation, and proinflammatory TNF-α and IFN-ɣ levels. ZnO/Ber NPs significantly decreased TREM-1 and MPO in association with elevated ACE II. In addition, ZnO/Ber NPs decreased the expression of apoptotic markers and decreased the number of alveolar inflammatory infiltrates to the minimal score. Molecular docking analysis revealed that ZnO/Ber NPs showed the strongest binding with all tested receptors.
Conclusion: ZnO/Ber NPs exhibit antioxidant, anti-apoptotic, and anti-inflammatory effects and act as therapeutic candidates against ARDS.
{"title":"Therapeutic potential of zinc oxide/berberine nanoparticles in mitigating acute respiratory distress syndrome: in vivo and in silico approaches.","authors":"Maysara S El-Salakawy, Alshimaa A Abd-Elmoneam, Mohammed S Nofal, Nourhan M Kolaib, Amany A Elkashef, Ahmed Z Ghareeb, Doaa A Ghareeb","doi":"10.1186/s40360-025-01036-5","DOIUrl":"10.1186/s40360-025-01036-5","url":null,"abstract":"<p><strong>Background: </strong>Inflammation and oxidative stress strongly contribute to the pathophysiology of acute respiratory distress syndrome (ARDS), which is a life-threatening pulmonary disease. Zinc oxide/berberine nanoparticles (ZnO/Ber-NPs) have been shown to have a protective effect against COVID-19 because of their antioxidant, anti-inflammatory, and antiviral properties. Hence, this study aimed to investigate the therapeutic action of ZnO/Ber NPs against ARDS. ARDS was induced by a combination of lipopolysaccharides and nicotine (LPS + Nt).</p><p><strong>Methods: </strong>Male mice were induced with LPS + Nt alternately for 14 days and then orally administered berberine (Ber) (1.24 mg/kg), ZnO NPs (2.06 mg/kg), a ZnO NP + Ber mixture (3.3 mg/kg), or ZnO/Ber NPs (3.3 mg/kg). Assessment of (1) prooxidant and antioxidant (enzymatic and nonenzymatic) parameters, (2) inflammatory and anti-inflammatory markers (TNF-α, IL-1β, IFN-ɣ, NF-kB and IL-10), (3) lung lesion parameters, triggering receptor expressed on myeloid cells-1 (TREM-1), myeloperoxidase enzyme (MPO) and angiotensin-converting enzyme-2 (ACE II), (4) and apoptotic markers (Bax and p53) were performed via standardized methods. In addition, ZnO, Ber, and ZnO/Ber NPs were examined for their bioactivities against the following proteins GPx, code: 2R37, SOD protein, code: 1PL4, ACE2 protein, code: 6M1D, TREM1 protein, code: 1Q8M and MPO protein, code: 6WYZ.</p><p><strong>Results: </strong>The results demonstrated that LPS + Nt administration significantly elevated oxidative stress, proinflammatory, lung lesion, and proapoptotic parameters while reducing antioxidant and ACE II levels in the lung. Treatments, especially ZnO/Ber NPs, significantly attenuated the oxidative stress and inflammation associated with ARDS, as indicated by the restoration of antioxidant enzyme activities, decreased lipid peroxidation, and proinflammatory TNF-α and IFN-ɣ levels. ZnO/Ber NPs significantly decreased TREM-1 and MPO in association with elevated ACE II. In addition, ZnO/Ber NPs decreased the expression of apoptotic markers and decreased the number of alveolar inflammatory infiltrates to the minimal score. Molecular docking analysis revealed that ZnO/Ber NPs showed the strongest binding with all tested receptors.</p><p><strong>Conclusion: </strong>ZnO/Ber NPs exhibit antioxidant, anti-apoptotic, and anti-inflammatory effects and act as therapeutic candidates against ARDS.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"205"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12670808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1186/s40360-025-01019-6
Galila Ragab Mebed, Mahmoud Sami Zakaria, Amr Setouhi, Meriam N N Rezk
{"title":"The correlation between Interleukin 1 β (IL-1β) as an inflammatory marker and Malondialdehyde (MDA) as a lipid peroxidation marker and the development of cardiac and pancreatic complications in humans suspected to scorpion poisoning.","authors":"Galila Ragab Mebed, Mahmoud Sami Zakaria, Amr Setouhi, Meriam N N Rezk","doi":"10.1186/s40360-025-01019-6","DOIUrl":"10.1186/s40360-025-01019-6","url":null,"abstract":"","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"204"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12670810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1186/s40360-025-01041-8
Khaled Abdul-Aziz Ahmed, Khalid M Alqaisi, Noralhuda Ayad Ibrahim, Sheylan Salah Abdullah, Ahmed A J Jabbar, Goran Noori Saleh, Dana K Alsharayiah, Abdulmohsen I Algefare, Mustafa Abdul-Monam, Manal A Alfwuaires, Talal Salem Al-Qaisi, Hanan Ibrahim Althagbi
The liver has a tremendous regeneration potential, yet chronic liver injury poses a life-threatening condition if not managed appropriately. Apocynin, an NADPH oxidase inhibitor, has been a central focus of attention in recent years due to its significant antioxidant/anti-inflammatory potentials. In this study, we evaluated the acute toxicity and hepatoprotective effects of Apocynin against thioacetamide (TAA)-induced liver fibrosis in rats. Liver fibrosis was induced by 200 mg/kg TAA three times/week for two months, along with treatment with distilled water (positive control), silymarin (reference, 50 mg/kg), or apocynin (50 and 100 mg/kg/day). Hepatic tissues were screened for histopathological, biochemical, and immunohistochemical changes, while hepatic homogenate was examined for the antioxidant contents (catalase, CAT; superoxide dismutase, SOD) and MDA levels. Apocynin treatment showed significant hepatoprotective effects against TAA-hepatotoxicity, evidenced by reduced hepatic tissue alterations with a slight fibroplasia, reduction of hepatomegaly, less hepatic nodules/necrosis, and recovered hepatic function. Additionally, apocynin administration reduced oxidative stress by lowering pro-oxidants (MDA) and up-regulating antioxidants (SOD and CAT). Furthermore, the anti-apoptotic and anti-fibrotic effects of apocynin were confirmed by reduced pro-apoptotic P53 proteins and β-catenin (tissue proliferation/aggregation enhancer). Apocynin treatment ameliorated ECM generation (lowered collagen bundles/fibrous septa) and reduced inflammatory (less TNf-α and IL-6 cytokines) mediators, all of which restored liver functional parameters (ALT, AST, ALP, and albumin). Apocynin attenuated TAA-mediated liver fibrosis by its modulatory potentials on several cytoprotective mechanisms associated with the oxidative stress/inflammation, making it a viable therapeutic source for liver fibrosis.
{"title":"Apocynin ameliorates liver fibrosis events in vivo through modulation of oxidative stress, inflammatory, and apoptotic mediators.","authors":"Khaled Abdul-Aziz Ahmed, Khalid M Alqaisi, Noralhuda Ayad Ibrahim, Sheylan Salah Abdullah, Ahmed A J Jabbar, Goran Noori Saleh, Dana K Alsharayiah, Abdulmohsen I Algefare, Mustafa Abdul-Monam, Manal A Alfwuaires, Talal Salem Al-Qaisi, Hanan Ibrahim Althagbi","doi":"10.1186/s40360-025-01041-8","DOIUrl":"10.1186/s40360-025-01041-8","url":null,"abstract":"<p><p>The liver has a tremendous regeneration potential, yet chronic liver injury poses a life-threatening condition if not managed appropriately. Apocynin, an NADPH oxidase inhibitor, has been a central focus of attention in recent years due to its significant antioxidant/anti-inflammatory potentials. In this study, we evaluated the acute toxicity and hepatoprotective effects of Apocynin against thioacetamide (TAA)-induced liver fibrosis in rats. Liver fibrosis was induced by 200 mg/kg TAA three times/week for two months, along with treatment with distilled water (positive control), silymarin (reference, 50 mg/kg), or apocynin (50 and 100 mg/kg/day). Hepatic tissues were screened for histopathological, biochemical, and immunohistochemical changes, while hepatic homogenate was examined for the antioxidant contents (catalase, CAT; superoxide dismutase, SOD) and MDA levels. Apocynin treatment showed significant hepatoprotective effects against TAA-hepatotoxicity, evidenced by reduced hepatic tissue alterations with a slight fibroplasia, reduction of hepatomegaly, less hepatic nodules/necrosis, and recovered hepatic function. Additionally, apocynin administration reduced oxidative stress by lowering pro-oxidants (MDA) and up-regulating antioxidants (SOD and CAT). Furthermore, the anti-apoptotic and anti-fibrotic effects of apocynin were confirmed by reduced pro-apoptotic P53 proteins and β-catenin (tissue proliferation/aggregation enhancer). Apocynin treatment ameliorated ECM generation (lowered collagen bundles/fibrous septa) and reduced inflammatory (less TNf-α and IL-6 cytokines) mediators, all of which restored liver functional parameters (ALT, AST, ALP, and albumin). Apocynin attenuated TAA-mediated liver fibrosis by its modulatory potentials on several cytoprotective mechanisms associated with the oxidative stress/inflammation, making it a viable therapeutic source for liver fibrosis.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"207"},"PeriodicalIF":2.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12670781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145653334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-29DOI: 10.1186/s40360-025-01044-5
Yasmina M Abd-Elhakim, Mohamed M M Hashem, Khaled Abo-El-Sooud, Mohamed R Mousa, Bayan A Hassan
Inorganic arsenical compounds, such as arsenic trioxide (ATO), are toxic environmental contaminants that occur widely in soil, water, and biological systems. Besides, zinc oxide nanoparticles (ZNPs) have been recently incorporated in various industrial and medicinal applications. Thus, their co-existence in the environment could widely occur. This study examined the potential protective activity of gallic acid (GA, 20 mg/kg b. wt) against the harmful impacts of 60-day co-exposure to ATO (8 mg ATO/kg b. wt) and ZNPs (100 mg ZNPs/kg b. wt) on the kidneys of rats. The results indicated that ZNPs and/or ATO exposure resulted in increased serum levels of markers associated with renal damage, an imbalance in electrolytes (sodium, potassium, and calcium), diminished levels of antioxidant enzymes in the kidneys, and an increased malondialdehyde (MDA) concentration. Furthermore, ZNPs and/or ATO co-exposed rats demonstrated markedly increased levels of renal zinc (Zn) and arsenic (As), accompanied by pronounced histopathological alterations, including interstitial nephritis, renal tubular necrosis, and vascular wall thickening. Immunohistochemical analysis revealed that exposure to ZNPs and/or ATO reduced the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) while increasing that of heat shock protein 90 (HSP90) in kidney tissues. Co-exposure to ZNPs and ATO produced more pronounced alterations, including increased serum uric acid and creatinine, decreased sodium levels, reduced renal GPx activity, increased MDA content, greater renal accumulation of As and Zn, and diminished Nrf2 expression, compared with individual exposures, suggesting additive toxic effects. However, GA notably reduced renal tissue damage, oxidative stress, and disturbances in renal function and electrolyte balance in rats co-exposed to ZNPs and ATO. Conclusively, the study found that exposure to ZNPs and ATO, especially when combined, was toxic to the kidneys, leading to impaired renal function through increased oxidative stress and disrupted electrolyte balance. However, GA effectively protected kidney health at the administered doses by counteracting these effects through its antioxidant properties and by modulating cellular defense mechanisms involving Nrf2 and HSP90.
无机砷化合物,如三氧化二砷(ATO),是有毒的环境污染物,广泛存在于土壤、水和生物系统中。此外,氧化锌纳米颗粒(ZNPs)最近已被纳入各种工业和医疗应用。因此,它们在环境中的共存可能会广泛发生。本研究检测了没食子酸(GA, 20 mg/kg b. wt)对大鼠肾脏共同暴露于ATO (8 mg ATO/kg b. wt)和ZNPs (100 mg ZNPs/kg b. wt) 60天的有害影响的潜在保护活性。结果表明,ZNPs和/或ATO暴露导致与肾损伤相关的血清标志物水平升高,电解质(钠、钾和钙)失衡,肾脏抗氧化酶水平降低,丙二醛(MDA)浓度升高。此外,ZNPs和/或ATO共同暴露的大鼠表现出肾脏锌(Zn)和砷(As)水平显著升高,并伴有明显的组织病理学改变,包括间质性肾炎、肾小管坏死和血管壁增厚。免疫组化分析显示,暴露于ZNPs和/或ATO可降低肾组织中核因子红细胞2相关因子2 (Nrf2)的表达,而增加热休克蛋白90 (HSP90)的表达。与单独暴露相比,ZNPs和ATO共同暴露产生了更明显的改变,包括血清尿酸和肌酐升高、钠水平降低、肾脏GPx活性降低、MDA含量增加、肾脏As和Zn积聚增加、Nrf2表达减少,表明了加性毒性作用。然而,GA显著降低了ZNPs和ATO共暴露大鼠的肾组织损伤、氧化应激以及肾功能和电解质平衡紊乱。最后,该研究发现,暴露于ZNPs和ATO,特别是同时暴露于ZNPs和ATO时,对肾脏有毒性,通过增加氧化应激和破坏电解质平衡导致肾功能受损。然而,在给药剂量下,GA通过其抗氧化特性和调节涉及Nrf2和HSP90的细胞防御机制来抵消这些影响,从而有效地保护肾脏健康。
{"title":"Gallic acid lessens kidney injury induced by inorganic arsenic and zinc oxide nanoparticles in rats via controlling electrolyte balance, oxidative stress, and Nrf-2 and HSP-90 expression.","authors":"Yasmina M Abd-Elhakim, Mohamed M M Hashem, Khaled Abo-El-Sooud, Mohamed R Mousa, Bayan A Hassan","doi":"10.1186/s40360-025-01044-5","DOIUrl":"10.1186/s40360-025-01044-5","url":null,"abstract":"<p><p>Inorganic arsenical compounds, such as arsenic trioxide (ATO), are toxic environmental contaminants that occur widely in soil, water, and biological systems. Besides, zinc oxide nanoparticles (ZNPs) have been recently incorporated in various industrial and medicinal applications. Thus, their co-existence in the environment could widely occur. This study examined the potential protective activity of gallic acid (GA, 20 mg/kg b. wt) against the harmful impacts of 60-day co-exposure to ATO (8 mg ATO/kg b. wt) and ZNPs (100 mg ZNPs/kg b. wt) on the kidneys of rats. The results indicated that ZNPs and/or ATO exposure resulted in increased serum levels of markers associated with renal damage, an imbalance in electrolytes (sodium, potassium, and calcium), diminished levels of antioxidant enzymes in the kidneys, and an increased malondialdehyde (MDA) concentration. Furthermore, ZNPs and/or ATO co-exposed rats demonstrated markedly increased levels of renal zinc (Zn) and arsenic (As), accompanied by pronounced histopathological alterations, including interstitial nephritis, renal tubular necrosis, and vascular wall thickening. Immunohistochemical analysis revealed that exposure to ZNPs and/or ATO reduced the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) while increasing that of heat shock protein 90 (HSP90) in kidney tissues. Co-exposure to ZNPs and ATO produced more pronounced alterations, including increased serum uric acid and creatinine, decreased sodium levels, reduced renal GPx activity, increased MDA content, greater renal accumulation of As and Zn, and diminished Nrf2 expression, compared with individual exposures, suggesting additive toxic effects. However, GA notably reduced renal tissue damage, oxidative stress, and disturbances in renal function and electrolyte balance in rats co-exposed to ZNPs and ATO. Conclusively, the study found that exposure to ZNPs and ATO, especially when combined, was toxic to the kidneys, leading to impaired renal function through increased oxidative stress and disrupted electrolyte balance. However, GA effectively protected kidney health at the administered doses by counteracting these effects through its antioxidant properties and by modulating cellular defense mechanisms involving Nrf2 and HSP90.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":" ","pages":"206"},"PeriodicalIF":2.7,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12670756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145629145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Topiramate (TPM) is a sulfamate-substituted monosaccharide known for its wide-ranging effects on epilepsy, neuropathic pain, and migraines. However, its precise influence on plasmalemmal ionic currents, including their magnitude and gating kinetics, remains uncertain. Therefore, a reassessment of the regulatory effect of TPM on ionic currents in electrically excitable cells is warranted.
Methods: With the aid of patch clamp technology, we investigated the effects of TPM on the amplitude, gating, and hysteresis of plasmalemmal ionic currents from GH3 lactotrophs.
Results: We observed that TPM exhibited a concentration-dependent inhibition of both transient (INa(T)) and late (INa(L)) components of INa, activated by brief depolarizing stimuli. At low concentration, TPM did not show any noticeable effect on INa(T); however, it was effective in reducing INa(L) amplitude. TPM caused a leftward shift in the midpoint of the steady-state inactivation curve of INa(T) without altering the gating charge. Importantly, the overall current density versus voltage relationship of INa(T) remained unaltered during TPM exposure. Intriguingly, the reduction in INa(T) induced by TPM could not be reversed by subsequent additions of flumazenil or chlorotoxin. Furthermore, TPM suppressed the density of the hyperpolarization-activated cation current (Ih). Simultaneously, the activation time course of Ih slowed in the presence of TPM. Moreover, TPM exposure decreased the hysteretic strength activated by double triangular ramp voltage, a change partially reversed by oxaliplatin. In current-clamp potential recordings, spontaneous action potentials were susceptible to suppression in the presence of TPM.
Conclusions: Collectively, these findings strongly suggest that TPM's effects on INa and Ih have the potential to impact the functional activities and electrical behaviors of excitable cells.
{"title":"Dual block evidence of the effects of topiramate, a sulfamate-substituted monosaccharide, on voltage-gated sodium current and hyperpolarization-activated cation current.","authors":"Ray-Chang Tzeng, Ming-Chi Lai, Sheng-Nan Wu, Chin-Wei Huang","doi":"10.1186/s40360-025-01043-6","DOIUrl":"https://doi.org/10.1186/s40360-025-01043-6","url":null,"abstract":"<p><strong>Background: </strong>Topiramate (TPM) is a sulfamate-substituted monosaccharide known for its wide-ranging effects on epilepsy, neuropathic pain, and migraines. However, its precise influence on plasmalemmal ionic currents, including their magnitude and gating kinetics, remains uncertain. Therefore, a reassessment of the regulatory effect of TPM on ionic currents in electrically excitable cells is warranted.</p><p><strong>Methods: </strong>With the aid of patch clamp technology, we investigated the effects of TPM on the amplitude, gating, and hysteresis of plasmalemmal ionic currents from GH<sub>3</sub> lactotrophs.</p><p><strong>Results: </strong>We observed that TPM exhibited a concentration-dependent inhibition of both transient (I<sub>Na(T)</sub>) and late (I<sub>Na(L)</sub>) components of I<sub>Na</sub>, activated by brief depolarizing stimuli. At low concentration, TPM did not show any noticeable effect on I<sub>Na(T)</sub>; however, it was effective in reducing I<sub>Na(L)</sub> amplitude. TPM caused a leftward shift in the midpoint of the steady-state inactivation curve of I<sub>Na(T)</sub> without altering the gating charge. Importantly, the overall current density versus voltage relationship of I<sub>Na(T)</sub> remained unaltered during TPM exposure. Intriguingly, the reduction in I<sub>Na(T)</sub> induced by TPM could not be reversed by subsequent additions of flumazenil or chlorotoxin. Furthermore, TPM suppressed the density of the hyperpolarization-activated cation current (I<sub>h</sub>). Simultaneously, the activation time course of I<sub>h</sub> slowed in the presence of TPM. Moreover, TPM exposure decreased the hysteretic strength activated by double triangular ramp voltage, a change partially reversed by oxaliplatin. In current-clamp potential recordings, spontaneous action potentials were susceptible to suppression in the presence of TPM.</p><p><strong>Conclusions: </strong>Collectively, these findings strongly suggest that TPM's effects on I<sub>Na</sub> and I<sub>h</sub> have the potential to impact the functional activities and electrical behaviors of excitable cells.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145629094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}